Can long-term twice-daily proton-pump inhibitor (PPI) therapy affect serum ferritin levels?

Can Long-Term Twice-Daily PPI Therapy Affect Ferritin Levels?

Yes, long-term twice-daily PPI therapy can significantly reduce serum ferritin levels and increase the risk of iron deficiency, particularly in patients taking higher doses for extended periods (≥1-2 years).

Evidence for Iron and Ferritin Depletion

The mechanism is straightforward: gastric acid is essential for converting dietary non-heme iron into its absorbable form, and PPIs suppress this acid production 1. Multiple lines of evidence demonstrate this effect:

Dose and Duration Matter Most:

• A large nested case-control study from Kaiser Permanente found that patients taking ≥1.5 PPI pills daily for ≥2 years had a significantly increased risk of iron deficiency (adjusted OR: 2.49) compared to those taking <0.75 pills daily 1
• The association only becomes clinically significant after ≥1 year of continuous use 1
• Twice-daily dosing represents the highest-risk scenario for iron depletion

Direct Ferritin Effects:

• A 2022 study showed significant reductions in serum ferritin (p<0.0001) with prolonged omeprazole use 2
• A 2018 prospective study found statistically significant changes in ferritin levels after 12 months of PPI use, though only 3.8% developed clinically significant hypoferremia 3

Clinical Implications from Guidelines

The 2022 AGA Clinical Practice Update on PPI de-prescribing explicitly addresses this concern 4:

Most patients on twice-daily PPIs should be stepped down to once-daily dosing. Double-dose PPIs (standard dose twice daily) are not FDA-approved and lack RCT support, yet up to 15% of PPI users receive higher-than-standard doses 4. This practice increases both costs and complication risks, including the micronutrient deficiencies discussed here.

Who Is at Highest Risk?

Monitor ferritin levels particularly closely in patients with:

• Twice-daily PPI dosing for ≥1-2 years (your specific scenario)
• Advanced age (>65 years) 1
• Baseline marginal iron stores or pre-existing anemia
• Malnutrition or restrictive diets
• Concurrent medications affecting iron absorption

Practical Management Algorithm

1. Reassess the indication: Does the patient truly need twice-daily dosing? Most GERD patients have non-erosive disease and don't require chronic PPIs at all 4

2. Step down if appropriate: Unless the patient has complicated GERD (severe erosive esophagitis LA grade C/D, Barrett's esophagus, peptic stricture), attempt reduction to once-daily dosing 4

3. Monitor ferritin: Check baseline ferritin before starting long-term PPIs, then annually in high-risk patients on twice-daily dosing

4. Consider iron supplementation: If ferritin drops below 30-45 ng/mL (modern cutoffs associated with iron deficiency) 5, consider oral iron supplementation—though note that PPI use may reduce its absorption

Important Caveats

• The clinical significance varies: while statistical reductions in ferritin occur consistently, frank iron deficiency anemia develops in only a minority of patients 3
• Genetic factors (SNPs in CYP2C19) may modify individual susceptibility 1
• Do not discontinue PPIs in patients with high GI bleeding risk (history of upper GI bleeding, multiple antithrombotics, or aspirin/NSAID use with additional risk factors) 4
• Warn patients about rebound acid hypersecretion if attempting de-prescribing 4

The bottom line: Your patient on twice-daily PPIs for years is at substantial risk for ferritin depletion and should have their PPI regimen reassessed for appropriateness, potentially stepped down to once-daily dosing, and monitored with periodic ferritin levels.